BioSpace News Archive

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), today announced it has entered into a strategic commercial supply agreement with CarThera® for the use of Lantheus’ microbubbles in combination with SonoCloud®, a proprietary implantable device in development for the treatment of recurrent glioblastoma (rGBM)

HitGen Inc. (“HitGen”) is pleased to announce that the company has entered into a strategic collaboration with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to design and build novel DNA-encoded libraries (“DELs”) to discover unique small molecule assets

ArQule, Inc. announced final results from the phase 1 study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase in patients with relapsed or refractory hematologic malignancies at the American Society of Hematology 2019 Annual Meeting & Exposition in Orlando, Florida.

Interim data show that patients with CLL achieved overall best objective response rate of 85% with progression-free survival of 100%

Psoriasis therapeutic market estimated to reach $11.4B in 2020

First and only subcutaneous immunoglobulin (SCIg) approved for maintenance therapy in CIDP qualifies for marketing exclusivity

Mr. Beck is succeeding Georgia Erbez on the Board of Directors and has been appointed as chair of the audit committee.

In the FREEDOM study, seizure freedom rates were 64.6% (n=31/48) and 77% (n=37/48) of newly diagnosed POS patients with secondarily generalized seizures receiving FYCOMPA 4 mg/day and FYCOMPA 4 and 8 mg/day, respectively at 26 weeks

Predictive Oncology Inc. announces updates on the commercialization of its CancerQuest 2020 initiative.

U.S.-based, state of the art facilities to be established for sustainable production of adjuvanted recombinant vaccine for use in the event of a pandemic